Literature DB >> 19996627

Prostatic ductal adenocarcinoma: a mini review.

Jonathan I Epstein1.   

Abstract

Prostatic ductal adenocarcinomas may arise either in large primary periurethral prostatic ducts or in the peripheral prostatic ducts. Ductal adenocarcinomas are composed of tall columnar cells arranged in cribriform, papillary, solid, single glands, and PIN-like patterns. Other than the prostatic intraepithelial neoplasia (PIN)-like ductal pattern, which behaves like Gleason pattern 3, ductal adenocarcinoma is comparable to Gleason pattern 4 prostate cancer. Ductal adenocarcinoma can have a patchy basal cell layer and typically expresses prostate-specific antigen (PSA) immunohistochemically. Mimickers of ductal adenocarcinoma include prostatic urethral polyps, hyperplastic benign prostate glands, high-grade PIN, colorectal adenocarcinoma, and papillary urothelial carcinoma. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2009        PMID: 19996627     DOI: 10.1159/000252842

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  18 in total

1.  Large cystic ductal carcinoma of the prostate: imaging findings and minimally invasive surgical treatment.

Authors:  Fabio Cesar Miranda Torricelli; Marcos Tucherman; Rodrigo Melogno; Rafael Ferreira Coelho
Journal:  BMJ Case Rep       Date:  2014-11-28

Review 2.  The update of prostatic ductal adenocarcinoma.

Authors:  Tantan Liu; Yingmei Wang; Ru Zhou; Haiyang Li; Hong Cheng; Jing Zhang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

3.  Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.

Authors:  Pedro Isaacsson Velho; John L Silberstein; Mark C Markowski; Jun Luo; Tamara L Lotan; William B Isaacs; Emmanuel S Antonarakis
Journal:  Prostate       Date:  2018-01-25       Impact factor: 4.104

4.  Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.

Authors:  Janet C Reid; Admire Matsika; Claire M Davies; Yaowu He; Amy Broomfield; Nigel C Bennett; Viktor Magdolen; Bhuvana Srinivasan; Judith A Clements; John D Hooper
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

5.  Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens.

Authors:  Amanda H Seipel; Fredrik Wiklund; N Peter Wiklund; Lars Egevad
Journal:  Virchows Arch       Date:  2013-02-27       Impact factor: 4.064

6.  Ductal adenocarcinoma of the prostate: a Hong Kong case series.

Authors:  Raymond Wai Man Kan; Chi Fai Kan; Joseph Hon Ming Wong; Kenneth Kam Fung Fu; Chi Fai Ng; Steve Wai Hee Chan
Journal:  Int Urol Nephrol       Date:  2014-07-31       Impact factor: 2.370

7.  Immunohistochemical profile of ductal adenocarcinoma of the prostate.

Authors:  Amanda H Seipel; Hemamali Samaratunga; Brett Delahunt; Fredrik Wiklund; Peter Wiklund; Johan Lindberg; Henrik Grönberg; Lars Egevad
Journal:  Virchows Arch       Date:  2014-07-25       Impact factor: 4.064

8.  Evaluation of tumor morphologies and association with biochemical recurrence after radical prostatectomy in grade group 5 prostate cancer.

Authors:  Trevor A Flood; Nicola Schieda; Jordan Sim; Rodney H Breau; Chris Morash; Eric C Belanger; Susan J Robertson
Journal:  Virchows Arch       Date:  2017-10-03       Impact factor: 4.064

9.  Prostatic ductal adenocarcinoma: An aggressive variant that is underdiagnosed and undersampled on transrectal ultrasound (TRUS)-guided needle biopsy.

Authors:  Previn Gulavita; Shaheed W Hakim; Nicola Schieda; Rodney H Breau; Chris Morash; Daniel T Keefe; Susan J Robertson; Kien T Mai; Eric C Belanger; Trevor A Flood
Journal:  Can Urol Assoc J       Date:  2015 Sep-Oct       Impact factor: 1.862

Review 10.  Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells.

Authors:  Andrew S Goldstein; Tanya Stoyanova; Owen N Witte
Journal:  Mol Oncol       Date:  2010-07-14       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.